What's new? Log in Free sign up

Pulse Biosciences (PLSE)

Company Profile

Company profile

Ticker

PLSE

Exchange

Website

www.pulsebiosciences.com

CEO

Mr. Burke T. Barrett

Incorporated

Location

Fiscal year end

Sector

Health Care and Social Assistance > Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers

Industry (SIC)

Surgical & Medical Instruments & Apparatus

3M • Stryker • FS KKR Capital • Boston Scientific • Solventum • Becton, Dickinson and • Blackstone Secured Lending Fund • Boardwalk Pipeline Partners • Domtar • Golub Capital BDC ...

Former names

[object Object]

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

NanoBlate Corp. • BioElectroMed Corp. • Pulse Biosciences BV • 2783162 Ontario Inc. ...

PLSE stock data

1M 3M 6M 1Y

Latest filings (excl ownership)

View all

Departure of Directors or Certain Officers

Regulation FD Disclosure

Pulse Biosciences Announces Positive Clinical Data Presented at the American Thyroid Association

Quarterly report

30 Oct 24

Pulse Biosciences Reports Business Updates and Third Quarter 2024 Financial Results

Quarterly report

19 Aug 24

Notice of late quarterly filing

Entry into a Material Definitive Agreement

Prospectus supplement for primary offering

Registration of additional securities for an S-3

Transcripts

View all

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Latest ownership filings

View all

Burke Thomas Barrett

ROBERT W DUGGAN

ROBERT W DUGGAN

ROBERT W DUGGAN

ROBERT W DUGGAN

Mitchell E. Levinson

Burke Thomas Barrett

Mahkam Zanganeh

ROBERT W DUGGAN

Kevin Patrick Danahy

Financial summary

Financial statements Chart PLSE financial data

Quarter (USD)	Sep 24	Jun 24	Mar 24	Dec 23
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	79.03 mm	79.03 mm	79.03 mm	79.03 mm	79.03 mm	79.03 mm
Cash burn (monthly)	(no burn)	(no burn)	4.55 mm	4.04 mm	3.01 mm	2.83 mm
Cash used (since last report)	n/a	n/a	12.82 mm	11.39 mm	8.47 mm	7.97 mm
Cash remaining	n/a	n/a	66.22 mm	67.65 mm	70.56 mm	71.06 mm
Runway (months of cash)	n/a	n/a	14.5	16.7	23.5	25.1

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q2 2024

PLSE institutional ownership history Ownership history

4.2% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	32	57	-43.9%
Opened positions	8	47	-83.0%
Closed positions	33	2	+1550.0%
Increased positions	12	1	+1100.0%
Reduced positions	7	5	+40.0%

13F shares	Current	Prev Q	Change
Total value	20.37 bn	31.96 bn	-36.3%
Total shares	2.34 mm	4.32 mm	-45.8%
Total puts	96.20 k	41.40 k	+132.4%
Total calls	138.30 k	224.70 k	-38.5%
Total put/call ratio	0.7	0.2	+277.5%

Largest owners	Shares	Value	Change
BAC Bank of America	782.58 k	$8.76 bn	NEW
Duggan Robert W	492.07 k	$4.30 mm	0.0%
STT State Street	391.64 k	$4.38 bn	+12.0%
Griffin Asset Management	257.68 k	$2.88 bn	-14.2%
Westside Investment Management	63.60 k	$711.68 mm	+97.8%
BK The Bank of New York Mellon Corporation	50.91 k	$569.73 mm	+23.4%
Spotlight Asset	40.29 k	$450.85 mm	-44.1%
MS Morgan Stanley	40.04 k	$448.08 mm	+8.3%
Millennium Management	38.54 k	$431.22 mm	NEW
Jane Street	28.71 k	$321.22 mm	+3.5%

Largest transactions	Shares	Bought/sold	Change
BLK BlackRock	0.00	-1.04 mm	EXIT
Vanguard	0.00	-847.21 k	EXIT
BAC Bank of America	782.58 k	+782.58 k	NEW
Geode Capital Management	0.00	-390.96 k	EXIT
NTRS Northern Trust	0.00	-187.14 k	EXIT
Renaissance Technologies	0.00	-61.40 k	EXIT
Griffin Asset Management	257.68 k	-42.64 k	-14.2%
STT State Street	391.64 k	+41.90 k	+12.0%
CWM Advisors	0.00	-41.36 k	EXIT
Millennium Management	38.54 k	+38.54 k	NEW

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

PLSE insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
18 Dec 24	Duggan Robert W	Common Stock		Acquire X	Yes	No	11	49,312	542.43 k	450,189
18 Dec 24	Duggan Robert W	Common Stock		Acquire X	Yes	No	11	69,020	759.22 k	630,109
18 Dec 24	Duggan Robert W	Common Stock		Acquire X	No	No	11	5,187,824	57.07 mm	47,516,541
18 Dec 24	Duggan Robert W	Warrants Common Stock		Dispose X	Yes	No	11	24,656	271.22 k	0
18 Dec 24	Duggan Robert W	Warrants Common Stock		Dispose X	Yes	No	11	24,656	271.22 k	0
18 Dec 24	Duggan Robert W	Warrants Common Stock		Dispose X	Yes	No	11	34,510	379.61 k	0
18 Dec 24	Duggan Robert W	Warrants Common Stock		Dispose X	Yes	No	11	34,510	379.61 k	0
18 Dec 24	Duggan Robert W	Warrants Common Stock		Dispose X	No	No	11	2,593,912	28.53 mm	0
18 Dec 24	Duggan Robert W	Warrants Common Stock		Dispose X	No	No	11	2,593,912	28.53 mm	0
13 Dec 24	Duggan Robert W	Common Stock	Buy	Acquire P	No	No	17.18	55,256	949.30 k	42,328,717

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

Pulse Biosciences,, On December 18, 2024, The Co's Co-Chairman And Majority Shareholder, Robert W. Duggan, Exercised All Of The Warrants He Acquired In The Co's 2024 Rights Offering, Corresponding To $58.4M Totaling To 5,306,156 Shares Of Company Common Stock

Pulse Biosciences, Inc. (NASDAQ:PLSE) (the "Company" or "Pulse Biosciences"), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™)

12 Health Care Stocks Moving In Friday's Intraday Session

Pulse Biosciences Presents European Feasibility Study Demonstrates Using Nano-PFA In Benign Thyroid Nodules Reduces Nodule Volume By Greater Than 50% And Provides Symptomatic Relief Within The First Month Of Treatment At the American Thyroid Association

European feasibility study demonstrates using nano-PFA in benign thyroid nodules reduces nodule volume by greater than 50% and provides symptomatic relief within the first month of treatmentPulse Biosciences, Inc.

Pulse Biosciences Q3 EPS $(0.21) Down From $(0.15) YoY

Press releases

From Benzinga Pro

Pulse Biosciences, Inc. Announces Planned Redemption of Warrants

Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced that it intends to deliver an

Pulse Biosciences, Inc. Announces Election to Exercise Company Warrants

Pulse Biosciences, Inc. (NASDAQ:PLSE) (the "Company" or "Pulse Biosciences"), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™)

Pulse Biosciences Announces Publication in the Journal of Thoracic and Cardiovascular Surgery

Preclinical data demonstrates advantages of the nano-PFA Cardiac Surgical System over radio frequency technology for ablation of cardiac tissue Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and

Pulse Biosciences Announces Positive Clinical Data Presented at the American Thyroid Association

Pulse Biosciences Announces Appointment of David Kenigsberg, M.D. as Chief Medical Officer of Electrophysiology

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.